Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China

Jin Zou,a Shuyan Chen,b,c Weiqiao Rao,d Liang Fu,e Jiancong Zhang,a Yunli Liao,d Ying Zhang,a Ning Lv,a Guofang Deng,e Shijin Yang,a Liang Lin,d Lujin Li,f Siqi Liu,d Jiuxin Qua

aDepartment of Clinical Laboratory, Shenzhen Third People's Hospital, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China
bCollege of Life Sciences, University of Chinese Academy of Sciences, Beijing, China
cShenzhen Third People’s Hospital, Second Hospital Affiliated to Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China
dBGI-Shenzhen, Shenzhen, China
eDivision Two of Pulmonary Diseases Department, Shenzhen Third People’s Hospital, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China
fCenter for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Jin Zou and Shuyan Chen contributed equally to this work. Author order was determined by drawing straws.

ABSTRACT Bedaquiline has been widely used as a part of combination dosage regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB) patients with limited options. Although the effectiveness and safety of bedaquiline have been demonstrated in clinical trials, limited studies have investigated the significant pharmacokinetics and the impact of genotype on bedaquiline disposition. Here, we developed a population pharmacokinetic model of bedaquiline to describe the concentration-time data from Chinese adult patients diagnosed with MDR-TB. A total of 246 observations were collected from 99 subjects receiving the standard recommended dosage. Bedaquiline disposition was well described by a one-compartment model with first-order absorption. Covariate modeling identified that gamma-glutamyl transferase (GGT) and the single-nucleotide polymorphism (SNP) rs319952 in the AGBL4 gene were significantly associated with the apparent clearance of bedaquiline. The clearance (CL/F) was found to be 1.4 L/h lower for subjects with allele GG in SNP rs319952 than for subjects with alleles AG and AA and to decrease by 30% with a doubling in GGT. The model-based simulations were designed to assess the impact of GGT/SNP rs319952 on bedaquiline exposure and showed that patients with genotype GG in SNP rs319952 and GGT ranging from 10 to 50 U/L achieved the targeted maximum serum concentration at steady state (Cmax,ss). However, when GGT was increased to 100 U/L, Cmax,ss was 1.68-fold higher than the highest concentration pursued. The model developed provides the consideration of genetic polymorphism and hepatic function for bedaquiline dosage in MDR-TB adult patients.

KEYWORDS population pharmacokinetics, bedaquiline, multidrug-resistant tuberculosis, GGT, rs319952

Tuberculosis (TB) has been the leading cause of death due to a single infectious agent worldwide since 2007, although it became the second leading cause of death in 2020 because of COVID-19 (1). China has been listed by WHO as one of the 10 countries in all three lists for “high-burden country” (HBC), for TB, HIV-associated TB, and multidrug-resistant TB (MDR-TB), in the period from 2021 to 2025. MDR-TB is defined as TB that resistant to at least the two most effective first-line drugs, isoniazid...
and rifampicin, and remains the greatest public health concern (2). The burden of MDR-TB is stable globally, and the rates of MDR-TB were estimated to be 3 to 4% in patients first diagnosed with TB and 18 to 21% of those previously treated for TB (1).

In 2012, bedaquiline (BDQ; formerly TMC207), the first in the new diarylquinoline class of antituberculosis drugs, became the first new drug to be approved by the U.S. Food and Drug Administration (FDA) for MDR-TB treatment in the past 40 years (3). The protonated active form binds to mycobacterial ATP synthase to kill the bacteria by interfering with proton transfer and inducing conformational changes of the ATP synthase (4, 5). In 2014, one phase 2b clinical trial reported that the addition of BDQ to the background regimen resulted in faster culture conversion and more significant culture conversions at 120 weeks compared to the results for the placebo group (6). At present, BDQ is classified in the group A drugs by WHO and recommended for the longer treatment regimens of MDR-TB, which have been used in 109 countries since 2019 (1, 7). The approved regimen of BDQ in adult patients includes 400 mg daily for 2 weeks, followed by 200 mg three times per week for another 22 weeks (8). The pharmacokinetic (PK) profile of BDQ shows that the maximum serum concentration (C\text{max}) is achieved about 5 h after administration, and the effective half-life is approximately 24 h after 2 weeks of 400-mg-daily dosing (8).

BDQ is mainly metabolized into a less active N-mono desmethyl metabolite (M2) and an N-didesmethyl metabolite (M3) by cytochrome P450 (CYP) isoenzyme CYP3A4, based on clinical trials (8). Other in vitro studies also reported that two novel metabolites (M5 and M6) were identified in human hepatocytes and that other CYP isoforms, CYP1A1, CYP2C8, CYP2C18, and CYP2C19, play a role in BDQ metabolism (9, 10). Data from two clinical trials indicated that the use of BDQ could be associated with an increased risk of death, QT interval prolongation, and hepatotoxicity (11). Although the underlying mechanisms of antituberculosis drug-induced hepatotoxicity (ATDH) have not been fully understood, genetic variants have been reported in association with ATDH susceptibility in Chinese and other populations, such as polymorphisms in drug-metabolizing enzymes N-acetyltransferase 2 (NAT2) and cytochrome P450 2E1 (CYP2E1) (12–15). In addition, other genetic predictors were suggested to play a role in the risk of ATDH in Chinese TB patients (16). Therefore, we included the analysis of genetic polymorphisms to explore the relationship between BDQ exposure and gene variants.

Three population pharmacokinetics models of BDQ in healthy adults and patients with tuberculosis were recently published (17–19). The first model was based on two clinical trials, including healthy volunteers, patients with drug-sensitive TB, and patients with MDR-TB, which characterized the effects of race and sex on apparent clearance (CL/F) and apparent central volume of distribution (Vc/F) individually (17). The second model described the PK of BDQ and its metabolite M2 in MDR-TB patients receiving 24 weeks of BDQ treatment. Significant covariates, such as weight, albumin, age, and race, were also characterized (18). A recently published model was developed to describe BDQ PK in Chinese patients with MDR-TB, but the significant covariates were not well characterized (19). In this study, we aimed to develop a population PK model of BDQ in Chinese MDR-TB patients and perform analysis of covariates and the association of genotype polymorphisms with variability in BDQ plasma PK.

RESULTS

Study population. A total of 246 BDQ concentrations were obtained from 99 patients who were recruited from October 2020 to October 2021. All patients were diagnosed with multidrug-resistant tuberculosis and orally administered the approved regimen. One patient provided eight samples, 1 patient provided seven samples, 5 patients provided six samples, 7 patients provided five samples, 11 patients provided four samples, 12 patients provided three samples, 24 patients provided two samples, and 38 patients provided one sample. Blood samples were randomly collected within a dosing interval at the steady-state on therapy that ranged from 2 to 64 weeks before...
PK sampling (median, 20 weeks). Only one observation was below the limit of detection (LOD) and replaced by the value of LOD in the assay, 0.024 μg/mL. The baseline demographic and clinical characteristics of the study population are summarized in Table 1. The distribution of the single-nucleotide polymorphisms (SNPs) of the 99 patients is shown in Table 2.

**Model building.** The population pharmacokinetics of BDQ was best characterized by a one-compartment model. The model was parameterized in terms of the apparent central volume of distribution ($Vc/F$), apparent clearance ($CL/F$), and absorption rate constant ($Ka$). The residual variability was best described by the proportional model. Based on graphical analysis, 7 covariates were found to be significantly related to $CL/F$, including age ($P = 0.0185$), sex ($P = 0.0272$), gamma-glutamyl transferase (GGT) concentration ($P = 0.000463$), and SNPs rs320003 (AA versus GG) ($P = 0.0268$), rs2031920 (CC versus TC&TT) ($P = 0.028$), rs11080344 (CC versus TC&TT) ($P = 0.0205$), and rs319952 (GG versus AA&AG) ($P = 0.0019$), and 3 covariates were significantly related to $Vc/F$, including GGT ($P = 0.0297$), total protein (TP) ($P = 0.0127$), and SNP rs9332096 (CC versus CT) ($P = 0.00354$) (Fig. 1). After a forward inclusion step, we found that GGT and SNP rs319952 significantly affected $CL/F$ ($P < 0.01$) and TP had significant effects on $Vc/F$ ($P < 0.01$). In the backward elimination step, only GGT and rs319952 were retained in the final model ($P < 0.005$). The final covariate model was as follows:

For rs319952 genotype A&AG,

$$CL/F = 4.54 \times (\text{GGT}/28.9)^{-0.476}$$  \hspace{1cm} (1)

And for rs319952 genotype G,

$$CL/F = 4.54 \times (\text{GGT}/28.9)^{-0.476} - 1.4$$  \hspace{1cm} (2)

The results showed that the higher the GGT, the lower the $CL/F$, and when the GGT increased by 30 U/L, the $CL/F$ decreased by 30%; when the genotype of rs319952 was G, $CL/F$ decreased by 1.4 L/h compared with A&AG. The parameter estimates of the final model are shown in Table 3.

**Model evaluation.** The goodness-of-fit plots of the final model showed that observations (OBS) were well correlated with the population prediction (PRED) and individual prediction (IPRED). The conditional weighted residual (CWRES) values were mostly distributed between ±6 and were evenly distributed on the upper and lower sides of
the coordinate axis, without apparent bias. The successful convergence rate of the bootstrap method for 1,000 resamples was 98.7%. The estimated PK parameter values from the original data set agreed with the median parameter estimate values from the bootstrap analysis (Table 3). The bootstrap analysis confirmed the robustness of the

| SNP    | Gene   | Allele  | No. of patients | Allelic frequency (%) |
|--------|--------|---------|-----------------|-----------------------|
| rs1045642 | ABCB1  | A       | 11              | 11.11                 |
|        |        | G (Ref) | 27              | 27.27                 |
|        |        | GA      | 45              | 45.45                 |
|        |        | NA      | 16              | 16.16                 |
| rs3740065 | ABCC2  | A (Ref) | 33              | 33.33                 |
|        |        | AG      | 40              | 40.40                 |
|        |        | G       | 10              | 10.10                 |
|        |        | NA      | 16              | 16.16                 |
| rs319952 | AGBL4  | A (Ref) | 31              | 31.31                 |
|        |        | AG      | 39              | 39.39                 |
|        |        | G       | 13              | 13.13                 |
|        |        | NA      | 16              | 16.16                 |
| rs320003 | AGBL4  | A       | 12              | 12.12                 |
|        |        | G (Ref) | 69              | 69.69                 |
|        |        | NA      | 18              | 18.18                 |
| rs2070401 | BACH1  | A (Ref) | 50              | 50.50                 |
|        |        | G       | 4               | 4.04                  |
|        |        | GA      | 29              | 29.29                 |
|        |        | NA      | 16              | 16.16                 |
| rs9332096 | CYP2C9 | C (Ref) | 77              | 77.78                 |
|        |        | CT      | 6               | 6.06                  |
|        |        | NA      | 16              | 16.16                 |
| rs4986893 | CYP2C19 | AG     | 7               | 7.07                  |
|         |        | G (Ref) | 76              | 76.77                 |
|         |        | NA      | 16              | 16.16                 |
| rs2031920 | CYP2E1 | C (Ref) | 46              | 46.46                 |
|         |        | T       | 3               | 3.03                  |
|         |        | TC      | 12              | 12.12                 |
|         |        | NA      | 38              | 38.38                 |
| rs1695  | GSTP1  | A (Ref) | 53              | 53.54                 |
|         |        | G       | 1               | 1.01                  |
|         |        | GA      | 28              | 28.28                 |
|         |        | NA      | 17              | 17.17                 |
| rs11080344 | NOS2  | C       | 29              | 29.29                 |
|         |        | T (Ref) | 18              | 18.18                 |
|         |        | TC      | 36              | 36.36                 |
|         |        | NA      | 16              | 16.16                 |
| rs10946739 | RIPOR2 | C (Ref) | 55              | 55.56                 |
|         |        | TC      | 28              | 28.28                 |
|         |        | NA      | 16              | 16.16                 |
| rs4149056 | SLCO1B1| C       | 8               | 8.08                  |
|         |        | T (Ref) | 59              | 59.60                 |
|         |        | TC      | 15              | 15.15                 |
|         |        | NA      | 17              | 17.17                 |
| rs1495741 | Unknown| A       | 18              | 18.18                 |
|         |        | AG      | 38              | 38.38                 |
|         |        | G (Ref) | 26              | 26.26                 |
|         |        | NA      | 17              | 17.17                 |
| rs11125883 | XPO1  | A (Ref) | 30              | 30.30                 |
|         |        | C       | 13              | 13.13                 |
|         |        | CA      | 40              | 40.40                 |
|         |        | NA      | 16              | 16.16                 |

aNA, not applicable.

Table 2 SNPs in the analysis of 99 patients
final model, indicating that the parameter estimation was stable and reliable. A prediction-corrected visual predictive check (PC-VPC) showed that most of the corrected observed concentrations fell within the 90% confidence intervals of the corrected predictive values, and the 90% confidence interval of the typical value predicted by the model basically overlapped the median of the observed value, indicating good predictive performance of the final model (Fig. 2).

### TABLE 3 Parameter estimates for the final model

| Parametera | Parameter estimate | Bootstrap analysis median value (5th–95th percentile)b | % shrinkage |
|-------------|--------------------|--------------------------------------------------------|-------------|
| Pharmacokinetic parameter | | | |
| \(K_a\) (h\(^{-1}\)) | 0.447 (16.6) | 0.443 (0.348 to 0.598) | |
| \(\text{CL/F} \, (\text{L/h})\) | 4.54 (5.3) | 4.52 (4.13 to 4.93) | |
| \(\text{Vc/F} \, (\text{L})\) | 227 (16.8) | 226 (179 to 316) | |
| Covariate parameter | | | |
| \(\sigma_{\text{GGT on CL/F}}\) | 0.476 (18.1) | 0.486 (0.645 to 0.340) | |
| \(\sigma_{\text{rs319952 on CL/F}}\) | 1.4 (27.1) | 1.35 (1.994 to 0.662) | |
| Interindividual variability (%) | | | |
| \(\eta_{\text{CL/F}}\) | 38.7 (10.7) | 37.8 (30.6 to 48.9) | 22.6 |
| \(\eta_{\text{Vc/F}}\) | 83.5 (12.5) | 82.7 (64.1 to 105.0) | 42.2 |
| Residual variability (%) | 32.2 (6.7) | 32.1 (28.7 to 35.9) | 17.4 |

\(a\)\(K_a\), absorption rate constant; \(\text{CL}\), clearance; \(\text{Vc}\), central volume of distribution; \(\sigma_{\text{prop}}\), proportional residual.
\(b\)RSE, relative standard error.
\(c\)The successful convergence rate of the bootstrap method for 1,000 resamples was 98.7%.
Dosage regimen simulation. Based on the final model, simulations were performed for the typical concentration-time curve with four concentrations of GGT (10 U/L, 30 U/L, 50 U/L, and 100 U/L) and the polymorphism at SNP rs319952 achieving the steady state under an oral dosage of 200 mg three times per week. As shown by the results in Fig. 3A and B, the exposure of BDQ with genotype GG in SNP rs319952 was significantly higher than that with genotypes AA and AG. When GGT achieved 30 U/L, the serum trough concentration ($C_{\text{min,ss}}$), $C_{\text{max,ss}}$, and area under the weekly concentration-time curve (AUCweekly) of patients with genotype GG were 1.75-fold, 1.3-fold, and 1.46-fold higher, respectively, than those of patients with genotypes AA and AG (Table 4).

A PK/PD analysis based on phase IIb data estimates that the half-maximal effective concentration (EC50) of BDQ is 1.42 mg/L (95% confidence interval [CI], 1.00 to 2.05) in the continuation phase of bedaquiline treatment (20). With the standard regimen, the trough and maximal concentrations ($C_{\text{min}}$ and $C_{\text{max}}$) of BDQ are 0.26 to 0.91 mg/L and 0.9 to 2.1 mg/L, respectively, at the end of the treatment period (200 mg three times per week) (18). In this study, the serum exposure of BDQ increased significantly as the GGT level rose. For the patients with genotype GG in SNP rs319952, those with GGT ranging from 10 U/L to 50 U/L could have $C_{\text{max,ss}}$ values of 0.959 to 2.046 mg/L, which were within the targeted concentrations, while $C_{\text{max,ss}}$ increased to 3.538 mg/L in a patient with a concentration of 100 U/L GGT, which was 1.68-fold higher than the highest concentration pursued (Table 4). However, for the patients with genotypes AA and AG, the $C_{\text{max,ss}}$ values of those with GGT ranging from 30 U/L to 100 U/L fell within the targeted concentrations, except that the $C_{\text{max,ss}}$ values of patients with 10 U/L GGT
were slightly lower than the lowest targeted concentration. Therefore, the dosage simulation indicated that the BDQ concentrations of patients with genotype GG and 100 U/L GGT should be monitored to avoid drug side effects caused by a high plasma concentration of BDQ.

DISCUSSION

In this work, we successfully developed a population PK model of the first drug in a new class of anti-TB drug, BDQ, among Chinese MDR-TB patients receiving standard BDQ treatment. A one-compartment with first-order-elimination model described the pharmacokinetic parameters of BDQ well. The relationship between GGT and CL/F was found to be statistically significant. In addition, this is the first model to include genotype polymorphism in the analysis, which takes advantage of the ability to characterize the covariate relationship between SNPs and BDQ PK, and simulation-based diagnostics indicate that the model robustly captures the observed data.

A four-compartment disposition model of BDQ was developed based on 10 clinical studies, including healthy adults and patients with drug-sensitive TB and MDR-TB, in which the majority of subjects were Black (31.0%) and Caucasian (27.9%) (17). Race and sex were observed to have a significant relationship with apparent clearance (CL/F) and apparent central volume of distribution (Vc/F). The other study analyzed data from two clinical trials (C208 and C209) and developed a population PK model for BDQ and its metabolite M2 where age, race, body weight, and albumin were significant covari-

**TABLE 4** BDQ dosage simulation targeting different levels of GGT and rs319952 genotypes

| Genotype | GGT concn (U/L) | AUC_{weekly,ss} (mg/L h) | C_{max,ss} (mg/L) | C_{min,ss} (mg/L) |
|----------|-----------------|--------------------------|------------------|------------------|
| A&AG     | 10              | 79.746                   | 0.859            | 0.176            |
|          | 30              | 134.529                  | 1.165            | 0.460            |
|          | 50              | 171.561                  | 1.377            | 0.666            |
|          | 100             | 238.620                  | 1.767            | 1.051            |
| G        | 10              | 97.977                   | 0.959            | 0.266            |
|          | 30              | 196.080                  | 1.519            | 0.806            |
|          | 50              | 286.080                  | 2.046            | 1.328            |
|          | 100             | 538.383                  | 3.538            | 2.815            |

**FIG 3** BDQ concentration-time curve with various levels of GGT and different rs319952 genotypes at steady state. (A) rs319952 genotype A&AG; (B) rs319952 genotype G.
ates (18). The estimate of apparent CL (2.62 L/h) was compared to the value presented by the first model (2.78 L/h). Here, we describe the BDQ disposition among Chinese patients by a one-compartment oral absorption model and present a higher value of CL (4.54 L/h), which may be due to the differences in patient race and physical condition. A recent study also based on Chinese MDR-TB patients, in which they collected at least two blood samples at weeks 1 and 2 with 400-mg-daily treatment and detected the plasma concentrations of BDQ, developed a three-compartment model with a transit absorption model for BDQ, but they calculated the smallest value for CL (1.50 L/h) (19). Consistent with the recent model of Chinese patients, body weight was not identified as a significant effect on PK in our work. Additionally, the second model predicts that the highest exposure of BDQ occurs in the first 2 weeks with 400 mg daily, followed by the actual steady state with a lower concentration and a slow accumulation during dosing of 200 mg thrice per week (18). Therefore, the differences in sampling times of the dosing state may be the reason for the large variation of CL/F values in these two Chinese studies.

Two covariates were found to be significant in apparent CL. Among the available 87 cases, the frequencies of genotypes AA, AG, and GG in SNP rs319952 (A > G) in the ATP/GTP-binding protein-like 4 gene (AGBL4) were 31.31%, 39.39%, and 13.13%, respectively, comparable to the previously published data for the Chinese Han population (43.8%, 44.7%, and 11.5%) (21). AGBL4, also known as CCP6, encodes the enzyme that participates in controlling assembly, trafficking, and signaling in the microtubules by posttranslational modification of tubulin (22). Our final model showed that the G allele had a 1.4-L/h decrease in CL/F compared to that of the AA or AG allele, which indicates that the subjects with the G allele had elevated exposure to BDQ. To our knowledge, there are no other genetic polymorphisms associated with BDQ exposure. However, previous studies proved that AGBL4 deficiency in mice resulted in enlarged spleens and increased platelet counts with underdeveloped mature megakaryocytes and dysfunctional platelets (23) and also substantially promoted induced pluripotent cell induction and pluripotency of embryonic stem cells (24). In genome-wide association studies (GWAS) in Ethiopian patients, the genetic polymorphisms in AGBL4, including the SNP rs319952, were found to be related to antituberculosis drug-induced liver toxicity, although this relationship was not reproduced in the Chinese Han population (21, 25). Therefore, the effect of increased susceptibility to liver toxicity caused by the AGBL4 genotype on BDQ metabolism needs to be further investigated. Given that BDQ is mainly metabolized by the enzyme CYP3A4 in hepatocytes, it is important to evaluate the effect of hepatic function on BDQ clearance. GGT has been widely used as an important indicator of liver dysfunction and an independent predictor of risk (26). In our model, we first identified that GGT was significantly associated with apparent CL, with a decrease of 30% in CL/F per doubling of GGT, suggesting the clinical potential of evaluating BDQ plasma concentration by GGT level.

Dosage simulation based on the final model demonstrated that the disposition of BDQ of patients with allele GG in SNP rs319952 was considerably higher than that with alleles AA and AG. As a GGT concentration of 30 U/L was achieved, patients with allele GG had $C_{\text{min,ss}}$, $C_{\text{max,ss}}$, and $\text{AUC}_{\text{weekly,ss}}$ values 1.75, 1.3, and 1.46 times higher than those of patients with alleles AA and AG (Table 4). Additionally, with increasing GGT concentrations, the plasma exposures of BDQ were markedly elevated. Taking patients with alleles AA and AG as examples, $C_{\text{min,ss}}$, $C_{\text{max,ss}}$, and $\text{AUC}_{\text{weekly,ss}}$ calculated from the 100 U/L GGT population were increased up to 5.97, 2.06, and 2.99 times, respectively, compared to those from the 10 U/L GGT population (Table 4). As the $C_{\text{max,ss}}$ of allele GG with 100 U/L GGT exceeded the highest target pursued (2.1 mg/L) by 1.68 times, the plasma exposure of BDQ under this condition needs special attention and monitoring.

In conclusion, we combined the related genotype polymorphisms to establish a population PK model for BDQ among Chinese MDR-TB patients. To our knowledge, this is the first study to identify the genetic polymorphisms in SNP rs319952 in the AGBL4 gene and glutamyl transferase as having a significant impact on BDQ clearance. Based on the final model, we simulated the BDQ exposure according to different alleles of rs319952 and GGT concentrations. The impact of covariates on BDQ PK might
provide potential clinical predictions for BDQ concentration by the rs319952 allele and GGT level in individualized medication.

**MATERIALS AND METHODS**

**Ethics.** Written informed consent was signed by all patients, and the study was approved by the Medical Research Ethics Committee of Shenzhen Third People's Hospital (reference no. 2021-003).

**Study subjects.** BDQ plasma concentration data were obtained from a prospective, open-label, population pharmacokinetic study conducted on MDR-TB patients in the Third People's Hospital of Shenzhen, China. The demographic characteristics for each patient were collected, and the laboratory examination results 2 days before or after PK sampling were used for analysis.

**Dosage and blood sampling.** All subjects received the tablet formulation with the approved regimen. 400 mg daily for the initial 2 weeks of treatment, followed by 200 mg three times per week for another 22 weeks. The other background drugs used included cycloserine (n = 91, 91.92%), linezolid (n = 96, 96.97%), pyrazinamide (n = 49, 49.49%), moxifloxacin (n = 41, 41.41%), clofazimine (n = 34, 34.34%), levofloxacin (n = 27, 27.27%), and ethambutol (n = 1, 1.01%). Blood samples were taken during weeks 3 to 24 (when patients were receiving the 200 mg three times per week dosage) and collected in EDTA-containing tubes. Samples were centrifuged within an hour at 3,000 × g at 4°C for 10 min, and then plasma was stored at −80°C.

**BDQ assay.** Plasma samples were used for BDQ quantification by liquid chromatography-tandem mass spectrometry (LC-MS/MS) after protein precipitation. Fifty microliters of plasma was deproteinized with 150 μL of precooled methanol containing internal standards. After centrifugation, the supernatant was analyzed by LC-MS/MS (LCMS-8040 CL; Shimadzu, Japan) with an electrospray ionization (ESI) source in positive ion mode. An ACE Excel C18-PFP column (2-μm particle size, 2.1 × 50 mm) was used for bedaquiline separation with a flow rate of 0.5 mL/min and column temperature of 45°C. The mobile phases consisted of water containing 0.1% formic acid (vol/vol) (mobile phase A) and acetonitrile/methanol (1:1) containing 0.1% formic acid (vol/vol) (mobile phase B). The gradient elution of 1% B was kept for 0.5 min and then changed linearly to 85% B to 98% B to 1% B during 3.1 min and maintained for 2.0 min. Multiple reaction monitoring (MRM) was used to monitor bedaquiline and the internal standards, with bedaquiline at m/z 555.2 to 58.0, internal standard at m/z 559.2 to 62.0, and collision energy (CE) at −25 V for bedaquiline and the internal standard. The mass parameters were as follows: nebulizer gas flow, 3.0 L/min, drying gas flow, 18 L/min, desolvation line (DL) temperature, 250°C, heating block temperature, 400°C, and interface voltage, 4.5 kV. Bedaquiline and the internal standard were purchased from Toronto Research Chemical (TRC). The range of the assay was 0.024 to 7.61 μg/mL.

**SNP selection and genotyping.** Genomic DNA was extracted from the peripheral blood samples using a nucleic acid isolation kit (magnetic beads) (DaAn Gene Co., Guangzhou, China). SNP genotyping was performed on the MassArray platform (Agena Bioscience) combined with the iPlex assay (Sequenom, Inc., Hamburg, Germany) and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. Ten nanograms of genomic DNA of each sample was standardized for genotyping. The DNA samples were amplified by multiplex PCR and treated with shrimp alkaline phosphatase, and then the products were subjected to a specific multiplex single-base extension PCR. The extension products were desalted using clean resin (MassArray clean resin, 28 g) and then transferred onto a SpectroChip array (Sequenom, Inc., Hamburg, Germany), where they were crystalized with a pre-supported MALDI matrix. The alleles were distinguished by MALDI-TOF mass spectrometry. Data were processed and analyzed automatically using Typer software (MassArray Typer 4.1.0.83).

**Population pharmacokinetic modeling of BDQ.** The BDQ concentration data were fitted by the one- or two-compartment with first-order-elimination model. An exponential model (equation 3) was used to account for interindividual variability (IIV), as follows:

\[
P_t = P_{\text{typical}} \times \exp(\eta_t)
\]

where \(P_t\) represents the individual PK parameter, \(P_{\text{typical}}\) represents the typical population value of the PK parameter, and \(\eta_t\) represents the individual variability, which is normally distributed with a mean of zero and variance of \(\sigma^2\).

Residual unexplained variability was tested by an additive model (equation 4), a proportional model (equation 5), or a combined additive and proportional model (equation 6), as follows:

\[C_{\text{obs},ij} = C_{\text{pred},ij} + \epsilon_{ij,\text{add}}\]

\[C_{\text{obs},ij} = C_{\text{pred},ij} \times (1 + \epsilon_{ij,\text{prop}})\]

\[C_{\text{obs},ij} = C_{\text{pred},ij} \times (1 + \epsilon_{ij,\text{prop}}) + \epsilon_{ij,\text{add}}\]

where \(C_{\text{obs}}\) and \(C_{\text{pred}}\) represent the observed values and the predicted values for plasma concentration, respectively, and \(\epsilon_{\text{add}}\) and \(\epsilon_{\text{prop}}\) represent the additive and proportional residuals, which were normally distributed with a mean of zero and variance of \(\sigma^2\) and \(\sigma^2\), respectively.

A covariate model was developed to evaluate the impact of covariates on the parameter. Continuous covariate relationships were modeled by equation 7, and categorical covariates were modeled using equation 8, as follows:
where \( P_{\text{typical}} \) represents the typical population value of the PK parameter, \( \text{COV}_{\text{median}} \) represents the median value of the covariate, and \( \theta \) represents a scale factor for the covariate.

We first used the graphical method to analyze the correlation between the covariates and PK parameters (\( Cl/F \) and \( Vc/F \)) and initially screened out the significantly correlated covariate/parameter relationships (\( P < 0.05 \)). If a subject’s continuous covariate was missing, it was filled with the median of the covariate, and if a subject’s categorical covariate was missing, it was filled with the classification with the highest frequency of occurrence. Then, the significantly correlated covariate/parameter relationships were further screened into the final model using a forward inclusion and backward elimination method. The forward inclusion and backward elimination steps were conducted at significance levels of \( \alpha = 0.01 \) and \( \alpha = 0.005 \), respectively, using the likelihood-ratio test. We also considered the pharmacological plausibility in the selection of the covariates.

The minimum value of objective function values (OFVs) served as a guide during model building. Model selection was also based on parameter plausibility and diagnosis plots. The goodness-of-fit for the final model was evaluated using diagnostic graphs. A nonparametric bootstrap analysis with 1,000 times resampling and replacement was performed, and the parameters that converged successfully were counted to obtain their medians and 95% confidence intervals. The prediction performance was evaluated through the PC-VPC (27). Based on the final population PK model, we simulated the typical BDQ exposure in steady state with different covariates under the standard dose regimen and calculated the PK parameters, such as \( Cl_{\text{median}}/Vc_{\text{median}} \) and \( \text{AUC}_{\text{weekly,ss}} \), to estimate the impact of covariates on BDQ exposure. The steady-state concentration was simulated by setting the SS Item in the NONMEM data file.

**Software.** Model development and simulation were performed using NONMEN 7.4 (level 1.0, ICON Development Solutions, USA). The first-order conditional-estimation method with interaction was used to estimate model parameters. A bootstrap procedure was performed using Wings for NONMEN (WFN741; http://wfn.sourceforge.net). R software (version 3.6.3) was used to process the output data, statistical analysis, and plotting.

**ACKNOWLEDGMENTS**

We thank Wei Jing from Beijing Chest Hospital for suggestions on PPK model development.

We acknowledge Guangdong Province Science and Technology Project (Tuberculosis) (grant number 2020B1111170014), Guangdong Basic and Applied Basic Research Foundation (grant number 2020A1515010586), Science and Technology Program of Shenzhen (grants number JCYJ20190809144005609, JCYJ20210324131212034, and JCYJ20180228162112889), Third People’s Hospital of Shenzhen (grants number G2021014 and G2021015), Shenzhen Science and Technology Innovation Committee (SZSTI) [grant number 20212871], and the State Key Laboratory of Infectious Disease Prevention and Control (grant number 2019SKLD302) for providing financial support for this research.

We declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**REFERENCES**

1. WHO. 2021. WHO Global tuberculosis report 2021. World Health Organization, Geneva, Switzerland.
2. Seung KJ, Keshavjee S, Rich ML. 2015. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 5:a017863. https://doi.org/10.1101/cshperspect.a017863.
3. Mahajan R. 2013. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res 3:1–2. https://doi.org/10.4103/2229-516X.112228.
4. Haagsma AC, Podasca I, Koul A, Andries K, Guillemont J, Lill H, Bald D. 2011. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One 6:e23575. https://doi.org/10.1371/journal.pone.0023575.
5. Guo H, Courbon GM, Bueler SA, Mai J, Liu J, Rubinstein JL. 2021. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline. Nat Commun 12:143–147. https://doi.org/10.1038/s41467-021-3004-z.
6. Diascon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paep E, van Heeswijk RP, Dannemann B, TMC207-C208 Study Group. 2014. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371:723–732. https://doi.org/10.1056/NEJMoa1313865.
7. WHO. 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.
8. Janssen Therapeutics. 2021. Sirturo (bedaquiline) package insert, FDA approved. Janssen Products, Titusville, NJ.
9. Liu K, Li F, Lu J, Liu S, Dorko K, Xie W, Ma K. 2014. Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos 42:863–866. https://doi.org/10.1124/dmd.113.056119.
10. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423.
11. Center for Drug Evaluation and Research. 2012. Application number: 204384 Orig1a000. Medical review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1a000MedR_pdf.pdf.
12. Du H, Chen X, Fang Y, Yan Q, Xu H, Li L, Li W, Huang W. 2013. Slow N-acetylttransferase 2 genotype contributes to anti-tuberculosis drug-induced
hepatotoxicity: a meta-analysis. Mol Biol Rep 40:3591–3596. https://doi.org/10.1007/s11033-012-2433-y.
13. Deng R, Yang T, Wang Y, Tang N. 2012. CYP2E1 Rsal/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 16:1574–1581. https://doi.org/10.5588/ijtld.12.0304.
14. Richardson M, Kirkham J, Dwan K, Sloan D, Davies G, Jorgensen A. 2017. Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol). Syst Rev 6:142. https://doi.org/10.1186/s13643-017-0533-4.
15. Jing W, Zong Z, Tang B, Wang J, Zhang T, Wen S, Xue Y, Chu N, Zhao W, Huang H. 2020. Population pharmacokinetic analysis of isoniazid among pulmonary tuberculosis patients from China. Antimicrob Agents Chemother 64:e01736-19. https://doi.org/10.1128/AAC.01736-19.
16. Wang Y, Xiang X, Huang WW, Sandford AJ, Wu SQ, Zhang MM, Wang MG, Chen G, He JQ. 2019. Association of PXR and CAR polymorphisms and antituberculosis drug-induced hepatotoxicity. Sci Rep 9:2217. https://doi.org/10.1038/s41598-018-38452-z.
17. McLeay SC, Vis P, van Heeswijk RP, Green B. 2014. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother 58:5315–5324. https://doi.org/10.1128/AAC.01418-13.
18. Svensson EM, Dosne AG, Karlsson MO. 2016. Population pharmacokinetics of bedaquiline and metabolite M2 in patients with drug-resistant tuberculosis: the effect of time-varying weight and albumin. CPT Pharmacometrics Syst Pharmacol 5:682–691. https://doi.org/10.1002/psp4.12147.
19. Zhu H, Xie L, Liu QZ, Wang B, Gao MQ, Lu Y. 2021. Population pharmacokinetics of bedaquiline in patients with drug-resistant TB. Int J Tuber Lung Dis 25:1006–1012. https://doi.org/10.5588/ijtld.21.0158.
20. Svensson EM, Karlsson MO. 2017. Modelling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant TB. J Antimicrob Chemother 72:3398–3405. https://doi.org/10.1093/jac/dkx317.
21. Pan H, Yang M, Lu L, Tao B, He X, Chen H, Yi H, Tang S. 2019. Association of FAM65B, AGBL4, and CUX2 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity: validation study in a Chinese Han population. Pharmacogenet Genomics 29:84–90. https://doi.org/10.1097/FPC.0000000000000370.
22. Rodriguez de la Vega Otazo M, Lorenzo J, Tort O, Aviles FX, Bautista JM. 2013. Functional segregation and emerging role of cilia-related cystosolic carboxypeptidases (CCPs). FASEB J 27:424–431. https://doi.org/10.1096/fj.12-209080.
23. Ye B, Li C, Yang Z, Wang Y, Hao J, Wang L, Li Y, Du Y, Hao L, Liu B, Wang S, Xia P, Huang G, Sun L, Tian Y, Fan Z. 2014. Cytosolic carboxypeptidase CCP6 is required for megakaryopoiesis by modulating Mad2 polyglutamylation. J Exp Med 211:2439–2454. https://doi.org/10.1084/jem.20141123.
24. Ye B, Liu B, Hao L, Zhu X, Yang L, Wang S, Xia P, Du Y, Meng S, Huang G, Qin X, Wang Y, Yan X, Li C, Hao J, Zhu P, He L, Tian Y, Fan Z. 2018. Klf4 glutamylation is required for cell reprogramming and early embryonic development in mice. Nat Commun 9:1261. https://doi.org/10.1038/s41467-018-03008-2.
25. Petros Z, Lee MM, Takahashi A, Zhang Y, Yimer G, Habtewold A, Amogne W, Adaraye G, Schuppe-Koistinen I, Mushiroda T, Makonnen E, Kubo M, Aklillu E. 2016. Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. BMC Genomics 17:755. https://doi.org/10.1186/s12864-016-3078-3.
26. Whitfield JB. 2001. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 38:263–355. https://doi.org/10.1080/20014091084227.
27. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143–151. https://doi.org/10.1208/s12248-011-9255-z.